Washington — President Trump said Friday he is canceling all orders signed by former President Joe Biden using an autopen, a mechanical device that reproduces signatures. "Any document signed" by ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Zeberiah Newman's documentary finds Susan Powter in Las Vegas and explores her life, celebrity and hopes for a comeback. By Daniel Fienberg Chief Television Critic Then again, Susan Powter was never ...

We all have miracles in our lives, and they happen every day. When I first began to study medicine, the intricacies of the human body and how it functions declared itself to me as one of G-d’s ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Tyler Perry is putting his spin on the classic holiday movie genre with his latest rom-com, “Finding Joy.” The movie, now streaming on Prime Video, follows the unlikely love story of Joy and Ridge, ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...

Fresh from launching his first Apple playlist earlier this year, King Charles is now fronting a new doc feature on Amazon Prime Video. “Finding Harmony: A King’s Vision,” set for release globally in ...

Florian Neukart does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...